Citius Pharmaceuticals, Inc. (CTXR) Stock Price & Analysis
Citius Pharmaceuticals, Inc. (CTXR) — MoonshotScore 21/100 (Weak band), calculated Nov 18, 2026. Price $0.5085 (+2.27%), as of the Nov 20, 2026 trading session; market cap $14.0M.
Educational signal · not a buy or sell recommendation · How to read this
Citius Pharmaceuticals, Inc. · CTXR · NASDAQ
Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing critical care products. Their pipeline includes anti-infective products, adjunct cancer care, prescription products, and mesenchymal stem cell therapy.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Citius Pharmaceuticals (CTXR)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality, a strained balance sheet and stalling growth, and it’s expensive on top — broad distress, a capital-preservation call, not a value entry. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Strained; Valuation: Full; Growth Durability: Fading; Momentum: Quiet.
- quarterly revenue $1M (Q3 FY2026, quarter ended Jun 30, 2026)
- EPS beat 2 of the last 8 reports
- Altman Z -4.04 · Piotroski F 3
Holding back: weak fundamentals, balance-sheet strain, soft growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 21 | Weak | |
| 21 | Weak | |
| 21 | Weak | |
| 21 | Weak | |
| 21 | Weak | |
| 21 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.5085 | |
| Change on the day | +2.27% | |
| Market capitalisation | $14.0M | — |
| Price / earnings (trailing) | -0.41 | |
| Shares traded on the day | 183.7K |
Price & events
Other perspectives
Council score for Citius Pharmaceuticals (CTXR): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 20, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company more favourably than the MoonshotScore does: Munger lens (margin of safety). Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as undervalued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Citius Pharmaceuticals (CTXR), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Citius Pharmaceuticals, Inc. (CTXR) is listed on NASDAQ. It employs 23 people. In Q3 FY2026 it reported revenue of $1M and net income of -$9M. The market values it at $14.0M.
What do the latest results show for Citius Pharmaceuticals (CTXR)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of $1M. Against analyst estimates the company has EPS beat 2 of the last 8 reports.
Quarterly income statement — 3 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | $1M | -$9M | -$0.34 (diluted) |
| Q2 FY2026 | $2M | -$21M | -$0.95 (diluted) |
| Q1 FY2026 | $4M | -$8M | -$0.38 (diluted) |
What are the financial strengths and risks for Citius Pharmaceuticals (CTXR)?
Short answer
What is holding it back is weak fundamentals, balance-sheet strain, soft growth. The distress and quality screens read Altman Z -4.04 · Piotroski F 3. Trailing ratios: ROE -81.1% · ROA -26.6% · current ratio 0.84.
Data-derived red flags
- Listing risk — at $0.5085 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
- Financial-distress signal — its Altman Z-Score of -4.04 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-81.1%) — the business is not currently generating profit on shareholder capital.
How does Citius Pharmaceuticals compare with its peers?
Short answer
Citius Pharmaceuticals's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.45 Nov 19, 2026 | $475M | 91 5-pillar Nov 18, 2026 | |
| $8.76 Nov 20, 2026 | $521M | 91 5-pillar Nov 18, 2026 | |
| $2.90 Nov 20, 2026 | $245M | 90 5-pillar Nov 18, 2026 | |
| $40.09 Nov 20, 2026 | $755M | 88 5-pillar Nov 18, 2026 | |
| $438.82 Nov 19, 2026 | $237B | 84 5-pillar Nov 18, 2026 | |
| $15.47 Nov 20, 2026 | $86.6M | 82 5-pillar Nov 18, 2026 | |
| $10.92 Nov 20, 2026 | $99.3M | 82 5-pillar Nov 18, 2026 | |
| $166.53 Nov 19, 2026 | $207B | 72 5-pillar Nov 18, 2026 | |
| $3.69 Nov 19, 2026 | $160M | 72 5-pillar Nov 18, 2026 | |
| $1.84 Nov 20, 2026 | $174M | 69 5-pillar Nov 18, 2026 | |
| $9.19 Nov 20, 2026 | $540M | 68 5-pillar Nov 18, 2026 | |
| $7.98 Nov 20, 2026 | $780M | 63 5-pillar Nov 18, 2026 | |
| Citius Pharmaceuticals (CTXR) — this page | $0.5085 | $14.0M | 21 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held CTXR in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported CTXR in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Citius Pharmaceuticals (CTXR)?
- Citius Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
- Citius Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London
- Citius Oncology's Positive Quality of Life Data for LYMPHIR® (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in Europe
Citius Pharmaceuticals Stock: Key Questions Answered
These answers are editorial: 1 of these 9 answers is drawn from the CTXR research dossier (written Jun 1, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for CTXR?
CTXR carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing critical care products.
Is CTXR a good stock to buy?
Stock Expert AI does not rate CTXR buy, sell or hold. Citius Pharmaceuticals, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the CTXR stock price today?
The last price recorded for Citius Pharmaceuticals, Inc. (CTXR), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What does Citius Pharmaceuticals, Inc. do?
Their primary focus is on anti-infective products, adjunct cancer care, prescription products, and mesenchymal stem cell therapy.
What are the key factors to evaluate for CTXR?
Citius Pharmaceuticals, Inc. (CTXR) holds a MoonshotScore in the low range. The timeline for this product is dependent on clinical trial progress and regulatory pathways. Not financial advice.
How frequently does CTXR data refresh on this page?
CTXR's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven CTXR's recent stock price performance?
Citius Pharmaceuticals, Inc. (CTXR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Pipeline of product candidates targeting unmet medical needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CTXR overvalued or undervalued right now?
Citius Pharmaceuticals, Inc. (CTXR) is loss-making, so its trailing P/E (listed under Price & valuation) is negative and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of CTXR?
Fractional-share availability for Citius Pharmaceuticals, Inc. (CTXR) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Jun 1, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 14 figures on this page — 9 from Financial Modeling Prep (FMP), 4 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com